Anthrax and other microbial threats
R e f e r e n c e s
1 World Health Organisation Report on Infectious Diseases. Removing obstacles to healthy development (available at http/:www.who.int/infectious-disease-report)
2 Task force on E.coli O157. Final report. June 2001. Scottish Executive. HM Stationary office (available at http://www.scotland.gov.uk/library3/health/ecoli.pdf)
3 Pittet D, Hugonnet S, Harbarth S. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 2000; 356: 1307-1312
4 Breman JG, Henderson DA. Poxvirus dilemmas: monkeypox, smallpox and biological terrorism. N Eng J Med. 1998; 339:556-559
5 Inglesby TV, Dennis DT, Henderson DA et al. Plague as a biological weapon: medical and public health management. JAMA 2000; 283: 2281-2290
6 Franz DR, Jahrling PB, Friedlander AM et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-403
7 Christopher GW, Cielak TJ, Pavlin JA, Eitzen EM. Biological warfare: a historical perspective. JAMA 1997; 278: 412-417
8 Cole LA. The spectre of biological weapons. Sci Am 1996: 275: 60-65
9 Meselson M, Guillemin J, Hugh-Jones M et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266: 202-1208
10 Manchee RJ, Brosler MG, Anderson IS, Henstridge RM, Melling J. Decontamination of B. anthracic on Gruinard Island. Nature 1983; 303: 239-240
11 Kaufmann AF, Meltzler MI, Schmid GP. The economic impact of a bioterrorist attack. Emerging Infect Dis 1997; 3: 83-94
12 Hanna P. How anthrax kills. Science 1998; 280: 1671
13 Fraser C, Dando M. Genomics and future biological weapons: the need for preventative action by the biomedical community. Nature Genetics; 2001: 29: 253-256
14 Anthrax as a biological weapon: Medical and Public Health Management. JAMA 1999; 281: 1735-1745
15 Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Natl Acad Sci USA 1993; 90:10198-10201.
16 Leppla SH. The anthrax toxin complex. In: Alouf J Freer JH eds. Sourcebook of bacterial protein toxins. London: Academic Press, 1991: 277-302
17 O’Brien J, Freidlander A, Dreier T, Ezzell J, Leppla S. Effects of anthrax toxin components on human neutrophils. Infect Immunol 1985; 47:306-10.
18 Duesbery NS, Webb CP, Leppla SH et al. Proteolytic inactivation of MAP- kinase-kinase by anthrax lethal factor. Science 1998; 280:734-7.
19 Hanna PC, Kochi S, Collier RJ. Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells. Mol Biol Cell 1992; 3:1269-77.
20 Dai Z, Sirard J-C, Mock M, Koehler TM. The atxA gene product actitates transcription of the anthrax toxin genes and is essential for virulence. Mol Microbiol 1995;16:1171-81
21 Dai Z, Koehler TM. Regulation of anthrax toxin activator gene (atx) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis. Infect Immunol 1997; 65:2576-82.
22 Turnbull PC. Anthrax vaccines: past, present and future. Vaccine 1991; 9:533-539.
23 Mourez M,. Kane R, Mogridge J, Metallo S, Daschatelets P, Sellman B, Whitesides G, Collier. Designing a polyvalent inhibitor of anthrax toxin. Nature Biotechnology 2001; 19: 958-961
24 Jernigan JA, Stephens DS, Ashford DA et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerging Infect Dis 2001; 7: 933-944
25 Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993;90:2291-2294
26 CDC. Update: Investigation of bioterrorism-related inhalational anthrax- Connecticut, 2001. MMWR; 2001;50: 1049-1051
27 Patra G, Vaissaire J, Weber-Levy M, Le Doujet C, Mock M. Molecular characterisation of Bacillus strains involved in outbreaks of anthrax in France in 1997. J Clin Microbiol 1998; 36:3412-4.
28 Turnbull PC. Definitive identification of Bacillus anthracis – a review. J Appl Microbiol 1999; 87; 237-40
29 Shylakhov E, Rubenstein E. Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax. Eur J Clin Microbiol Infect Dis 1996;15:242-5
30 Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A Streptococcal infection in mice. Am J Med 1952; 13: 389-399
31 Gemmell CG, Peterson PK, Schmeling D et al. Potentiation of opsonisation and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981; 67: 1249-1256
32 Swartz MN. Recognition and Management of Anthrax- an update. N Eng J Med 2001; 345: 1621-1626.
33 Turnbull PC. Anthrax vaccines: past, present and future. Vaccine 1991; 9:533-539.
34 Bradley K, Mogridge J, Mourez M, Collier J, Young J. Identification of the cellular receptor for anthrax toxin. Nature 2001; 414: 225-229
35 Pannifer A, Wong TY, Schwarzenbacher R, Renatus M, Petosa C, Bienkowska J, Lacy DB, Collier J, Park S, Leppla S, Hanna P, Liddington R. Crystal structure of the anthrax lethal factor. Nature 2001; 414: 229-233
36 Watters JW et al. Kif1C, a kinesin-like motor protein, mediates mouse macrophages resistance to anthrax lethal factor. Current Biology, 2001; 11: 1503 –1511
37 Torok TJ, Tauxe RV, Wise RP et al. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 1997; 287: 384-395
38 Hart CA, Beeching N. Prophylactic treatment of anthrax with antibiotics. Br Med J; 2001; 323: 1017-1018
39 Fox J. Adjusting FDA policies to address bioterrorist threat. Business and regulatory news. 1999; 17: 323-324
40 Cohen HW, Sidel VW, Gould RM. Preparedness for Bioterrorism? N Eng J Med; 2001; 345: 1423
41 Spencer RC, Lightfoot NF. Preparedness and response to bioterrorism. J Infect 2001; 43: 104-110